The Effect of Dehydroepiandrosterone Sulfate (DHEAS) on Myotonia: Intracellular Studies

  • NAKAZORA Hiroshi
    Division of Neurology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo
  • KURIHARA Teruyuki
    Division of Neurology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo

書誌事項

タイトル別名
  • Effect of Dehydroepiandrosterone Sulfate DHEAS on Myotonia Intracellular Studies

この論文をさがす

説明

Objective In order to find some appropriate medicine to suppress myotonia without decreasing muscle strength experiments were performed on myotonic (mto) mice whose Cl channel does not develop due to stop codon and serves as an animal model of myotonia. In myotonic dystrophy dehydroepiandrosterone is low in the serum and it has been reported that intravenous injections of DHEAS to human cases improves myotonia and activities of daily living.<br>Materials and Methods Three pairs of heterozygote mto mice, SWR/J-Clcn1adr-mto/+ and ten Wistar rats were used. We performed intracellular recordings of myotonia from mto mice and the drug effects on insertion myotonia were recorded from the hemidiaphragm preparations of mto mice with different concentrations of DHEAS. Isometric twitch tension was recorded from rat hemidiaphragm preparations in Tyrode’s solution and the effect of DHEAS on the muscle twitch tension was measured at different concentrations of DHEAS from 100 mg/l to 300 mg/l. The effect of mexiletine on ITT was also measured.<br>Results In mto mice insertion myotonia was recorded as soon as the microeletrode was inserted in the muscle cells. When DHEAS was added to Tyrode’s solution, insertion myotonia was suppressed. DHEAS decreased ITT up to 70% of the original value, though mexiletine decreased ITT to 30% of the original value. Therefore, the decrement of the muscle strength in DHEAS solution is much smaller than that of mexiletine.<br>Conclusion Since myotonic dystrophy shows progressive muscle weakness in addition to myotonia, medications like DHEAS are more favorable than the typical Na channel blocker.

収録刊行物

  • Internal Medicine

    Internal Medicine 44 (12), 1247-1251, 2005

    一般社団法人 日本内科学会

被引用文献 (1)*注記

もっと見る

参考文献 (34)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ